Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Solid Tumors
NCT01989585Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2014
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of navitoclax in melanoma, solid tumor, sponsored by National Cancer Institute. Started Mar 2014; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT01989585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01989585.